$ONC · BeOne Medicines Ltd.
BeOne Medicines (formerly BeiGene) filed its Q3 FY2026 10-Q. Total revenue grew 33.8% YoY to $1.89B, driven by product revenue of $1.86B (+33.0%). Net income reached $384.7M versus $124.8M in Q3 2025, with diluted EPS of $0.25 (GAAP) and $0.35 adjusted. Gross margin was 88.5% and operating margin 22.2%. Nine-month revenue was $5.11B (+32.9%) with net income of $849.1M.
- Q3 revenue $1.89B, up 33.8% YoY; product revenue $1.86B up 33.0%.
- Net income $384.7M vs $124.8M a year ago, up 208.2%.
- Nine-month net income $849.1M vs $220.4M, up 285.2%.
- Gross margin 88.5%; operating margin 22.2%.
- Cash and equivalents $5.78B at Sept 30, 2026, up from $4.55B at year-end.
Extended-hours last trade $400.00, +5.88% vs regular close of $377.78, signaling a positive after-hours reaction to the strong results.
BeOne's triple-digit net income growth and 33.8% revenue expansion confirm accelerating commercial momentum in oncology.
BeOne's 33.8% revenue growth and 88.5% gross margin reflect strong commercial execution in oncology, outpacing many large-cap biopharma peers.
A $22.0M developed product intangible impairment was recorded on the decision to discontinue promotion of POBEVCY. Interest expense rose 159.1% YoY to $42.4M.